Bevacizumab application delays epithelial healing in rabbit cornea

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4653-4659

  Kim, Tae Im ^b   Chung, Jae Lim ^b   Hong, Jin Pyo ^b   Min, Kyung ^b   Seo, Kyoung Yul ^b   Kim, Eung Kweon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; BETA INTEGRIN; BETA1 INTEGRIN; BETA2 INTEGRIN; BEVACIZUMAB; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; INTEGRIN; KI 67 ANTIGEN; MESSENGER RNA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; CORNEA; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; DEBRIDEMENT; DRUG EFFICACY; EXPERIMENTAL RABBIT; FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WOUND CLOSURE; WOUND HEALING IMPAIRMENT; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; INJURY; METABOLISM; RABBIT; TIME; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; COLLAGEN TYPE I; COLLAGEN TYPE IV; DEBRIDEMENT; DISEASE MODELS, ANIMAL; EPITHELIUM, CORNEAL; FIBROBLASTS; INTEGRIN ALPHA CHAINS; INTEGRIN BETA CHAINS; KI-67 ANTIGEN; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 70349577522     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2805     Document Type: Article

References (38)

1. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
3. Yan J, Zeng Y, Jiang J, et al. The expression patterns of vascular endothelial growth factor and thrombospondin 2 after corneal alkali burn. Colloids Surf B Biointerfaces. 2007;60:105-109.
4. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol. 1991;139:961-967.
5. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69:475-482.
6. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1995;268:447-448.
7. Dell S, Peters S, Müther P, et al. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:1928-1937.
8. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557-563.
9. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
10. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
11. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002.e1-e12.
12. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056.
13. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004;9 Suppl 1:11-18.
14. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
15. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
16. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008 Jul.;27(6): 743-745.
17. Bock F, König Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008 Feb.;246(2):281-284.
18. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-8.
19. Robinson CJ, Stringer SE. The splicing variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001; 114:853-865.
20. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004; 45:368-374.
21. Heidenreich R, Murayama T, Silver M, et al. Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice. J Vasc Res. 2008;45:437-444.
22. Chang SW, Chou SF, Chuang JL. Mechanical corneal epithelium scraping and ethanol treatment up-regulate cytokine gene expression differently in rabbit cornea. J Refract Surg. 2008;24:150-159.
23. Jester JV, Huang J, Fisher S, et al. Myofibroblast differentiation of normal human keratocytes and hTERT, extended-life human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2003;44:1850-1858.
24. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
25. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
26. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
27. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328.
28. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352.
29. Vigneault F, Zaniolo K, Gaudreault M, et al. Control of integrin genes expression in the eye. Prog Retin Eye Res. 2007;26:99-161.
30. Masur SK, Cheung JK, Antohi S. Identification of integrins in cultured corneal fibroblasts and in isolated keratocytes. Invest Ophthalmol Vis Sci. 1993;34:2690-2698.
31. Soro S, Orecchia A, Morbidelli L, et al. A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin. Blood. 2008 1;111:3479-3488.
32. Muether PS, Dell S, Kociok N, et al. The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp Eye Res. 2007;85:356-365.
33. Pepper MS, Mandriota SJ, Vassalli J-D, et al. Angiogenesis-regulating cytokines: activities and interactions. Curr Top Microbiol Immunol. 1996;213:31-67.
34. Chen L, Huq S, Gardner H, et al. Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol. 2007;125:783-788.
35. Dietrich T, Onderka J, Bock F, et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol. 2007;171:361-372.
36. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci. 1996;93:9764-9769.
37. Senger DR, Claffey KP, Benes JE, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through ß1 and 2ß1. Proc Natl Acad Sci. 1997;94:13612-13617.
38. Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156:1345-1346.